The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
about
Pediatric AML: From Biology to Clinical ManagementGene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AMLMolecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations.Acute promyelocytic leukemia: a case-based review.Molecular markers in myeloproliferative disorders: from classification to prognosis?Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysisGPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemiaMolecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysisCorrelation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia.Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia.BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia.Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.Genomics in multiple myeloma: biology and clinical implications.Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis.Soluble Flt-1 gene delivery in acute myeloid leukemic cells mediating a nonviral gene carrier.Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis.Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.Application of the AMLprofiler Diagnostic Microarray in the South African Setting.Molecular predictors of post-transplant survival in acute myeloid leukemia.Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.Trisomy 21 with t(5; 11) chromosomal translocation as new unfavorable cytogenetic abnormalities in pediatric acute myeloid leukemia type M2: One case report of nine-year follow-up and literature review.Measurement of Residual Disease in Acute Myeloid Leukemia.Fluorescent In Situ Hybridization in Suspension by Imaging Flow Cytometry.
P2860
Q26799773-FEF545CF-498E-4C66-A1C0-F67D64BCF220Q33538325-B055C93D-8A25-49A4-ACC2-744855FBCEC3Q33555627-5CECC8AB-ED61-4403-9CBB-EFB67CF84CA5Q33556923-D9EEAD66-6E7F-4C53-9505-AB7D5F0F419CQ34244973-AB393E2D-725A-41D8-A7F4-A532A5B58B29Q35127005-4E17CCF1-3767-4479-9888-D955BE8EBD41Q35197150-3572C989-8C87-4A08-899C-EB7819DC8E72Q35750567-47D22975-38F5-492B-8124-5A6AB73912B3Q35783433-5C167C9E-DC68-4B5A-97F3-A4EB03C6CF93Q35835260-8F9C4E56-4B98-4E55-B50B-FB8EE68F404CQ35854158-77A64079-58E8-4575-A43A-B3B73846E38AQ36153422-0299FB62-83CE-482E-8018-B6C821F327DAQ36439908-D30588B1-168A-4982-BC55-201CBFAF5F66Q37084121-A2762C0A-0797-42E9-B335-E72C0DF559A5Q37675993-97944BCA-752A-4912-BB04-E8AE8BCDBF78Q38207607-7A8A9880-3551-423B-A19A-9A3DBFB3D92FQ38240563-719ED4C8-E7C3-43DF-93B2-AF7EA604AF80Q38537879-40358402-975C-4370-85DB-4A75AC2A1BACQ38724266-2BA3CDED-8F82-4027-87C7-77AD17120131Q38804780-9C2564F7-5649-4DA9-AC5A-384D6FA52FF8Q38819676-B1B40DAD-2FDB-439A-B8BC-5FB3BC9A9828Q38839165-D424FD6A-D55B-4AD6-8CE2-EC935EB1138FQ39888679-4CA81DC5-8801-414B-BBFF-7B06705FDECDQ40391459-9C11D58E-3F6E-4AF5-B51F-00308222E51EQ40601089-9C356098-8EC7-459D-B9C3-D6781E58A193Q40827250-B9B441CF-5628-4610-B230-D8F23EF6ABB9Q41847123-AB2A3B72-E615-434B-B275-FEA6565FA1FAQ42182112-49F9EEB1-FF49-4B29-9615-A4660716EB30Q44336225-C269A8EB-1152-4C12-936D-F80D00649A56Q46606851-8F168B5C-C743-4F1F-B0A7-692BF297906FQ47102086-44EC5BB2-E119-4525-B4EA-36CDCF2EC3B2Q47256283-1C34A50A-3E29-491E-8162-2867268EDDA3Q47619423-1F5872BF-5C1A-48E0-93FD-91FC3E5FA6B7Q47829263-56855490-5A9C-4D45-9219-8181577AEAFDQ47928900-F91DB9CC-54E9-4524-9A27-62463427226CQ48262712-BEB5712C-28BB-410F-9EBA-1C10E6B10897Q48446071-1F1F5E18-91A5-41F8-85EE-684834BAAE51Q50067507-9A82CE30-730E-4793-A93D-7BA9F76A350DQ50075132-6528A7A4-E825-4BFA-8B81-E1A2DC1ECD1FQ50257254-000DB322-A461-4711-858E-D6545E43AE1C
P2860
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@ast
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@en
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@nl
type
label
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@ast
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@en
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@nl
prefLabel
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@ast
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@en
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@nl
P356
P1476
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.
@en
P2093
Grimwade D
P304
P356
10.1053/BEHA.2001.0152
P577
2001-09-01T00:00:00Z